Stocks · News reference
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 5.56 percent increase over losses of $(0.72) per share
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Thursday, Denali Therapeutics (NASDAQ:DNLI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call
B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.
UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.